- Home
- MGYR vs BMEA Comparison
MGYR vs BMEA Comparison
Compare MGYR & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGYR
- BMEA
- Stock Information
- Founded
- MGYR 1922
- BMEA 2017
- Country
- MGYR United States
- BMEA United States
- Employees
- MGYR N/A
- BMEA N/A
- Industry
- MGYR Savings Institutions
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MGYR Finance
- BMEA Health Care
- Exchange
- MGYR Nasdaq
- BMEA Nasdaq
- Market Cap
- MGYR 110.9M
- BMEA 114.3M
- IPO Year
- MGYR 2006
- BMEA 2021
- Fundamental
- Price
- MGYR $17.44
- BMEA $2.04
- Analyst Decision
- MGYR
- BMEA Strong Buy
- Analyst Count
- MGYR 0
- BMEA 10
- Target Price
- MGYR N/A
- BMEA $15.70
- AVG Volume (30 Days)
- MGYR 5.7K
- BMEA 614.1K
- Earning Date
- MGYR 10-30-2025
- BMEA 10-28-2025
- Dividend Yield
- MGYR 2.08%
- BMEA N/A
- EPS Growth
- MGYR 35.01
- BMEA N/A
- EPS
- MGYR 1.57
- BMEA N/A
- Revenue
- MGYR $35,533,000.00
- BMEA N/A
- Revenue This Year
- MGYR N/A
- BMEA N/A
- Revenue Next Year
- MGYR N/A
- BMEA N/A
- P/E Ratio
- MGYR $11.04
- BMEA N/A
- Revenue Growth
- MGYR 18.29
- BMEA N/A
- 52 Week Low
- MGYR $12.10
- BMEA $1.29
- 52 Week High
- MGYR $19.04
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- MGYR 55.49
- BMEA 59.68
- Support Level
- MGYR $17.01
- BMEA $1.86
- Resistance Level
- MGYR $17.45
- BMEA $2.11
- Average True Range (ATR)
- MGYR 0.26
- BMEA 0.12
- MACD
- MGYR -0.01
- BMEA 0.01
- Stochastic Oscillator
- MGYR 64.18
- BMEA 78.64
About MGYR Magyar Bancorp Inc.
Magyar Bancorp Inc is a mid-tier stock holding company. The Company offers a full array of commercial and retail financial services, including the taking of time, savings and demand deposits; the making of commercial, consumer and home equity loans; and the provision of other financial services. The business consists of getting retail deposits from the general public in the areas surrounding the main office in New Brunswick, New Jersey and branch offices located in Middlesex and Somerset Counties, New Jersey, and investing those deposits, together with funds generated from operations and wholesale funding, in residential mortgage loans, home equity loans, home equity lines of credit, commercial real estate loans, commercial business loans, Small Business Administration loans.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.